316 related articles for article (PubMed ID: 38605087)
1. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.
Zhu B; Yin H; Zhang D; Zhang M; Chao X; Scimeca L; Wu MR
Cell Mol Immunol; 2024 May; 21(5):436-447. PubMed ID: 38605087
[TBL] [Abstract][Full Text] [Related]
2. Engineering advanced cancer therapies with synthetic biology.
Wu MR; Jusiak B; Lu TK
Nat Rev Cancer; 2019 Apr; 19(4):187-195. PubMed ID: 30837696
[TBL] [Abstract][Full Text] [Related]
3. A synthetic biology approach to engineering circuits in immune cells.
Hoces D; Miguens Blanco J; Hernández-López RA
Immunol Rev; 2023 Nov; 320(1):120-137. PubMed ID: 37464881
[TBL] [Abstract][Full Text] [Related]
4. Synthetic biology approaches in cancer immunotherapy, genetic network engineering, and genome editing.
Chakravarti D; Cho JH; Weinberg BH; Wong NM; Wong WW
Integr Biol (Camb); 2016 Apr; 8(4):504-17. PubMed ID: 27068224
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
Kalos M; June CH
Immunity; 2013 Jul; 39(1):49-60. PubMed ID: 23890063
[TBL] [Abstract][Full Text] [Related]
7. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
8. Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy.
Shih RM; Chen YY
Cancer Immunol Res; 2022 Jan; 10(1):6-11. PubMed ID: 34983828
[TBL] [Abstract][Full Text] [Related]
9. Synthetic biology in cell-based cancer immunotherapy.
Chakravarti D; Wong WW
Trends Biotechnol; 2015 Aug; 33(8):449-61. PubMed ID: 26088008
[TBL] [Abstract][Full Text] [Related]
10. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
11. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
12. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.
Magalhaes I; Carvalho-Queiroz C; Hartana CA; Kaiser A; Lukic A; Mints M; Nilsson O; Grönlund H; Mattsson J; Berglund S
Expert Opin Biol Ther; 2019 Aug; 19(8):811-827. PubMed ID: 30986360
[TBL] [Abstract][Full Text] [Related]
13. Synthetic mammalian gene circuits for biomedical applications.
Ye H; Aubel D; Fussenegger M
Curr Opin Chem Biol; 2013 Dec; 17(6):910-7. PubMed ID: 24466575
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.
Leventhal DS; Sokolovska A; Li N; Plescia C; Kolodziej SA; Gallant CW; Christmas R; Gao JR; James MJ; Abin-Fuentes A; Momin M; Bergeron C; Fisher A; Miller PF; West KA; Lora JM
Nat Commun; 2020 Jun; 11(1):2739. PubMed ID: 32483165
[TBL] [Abstract][Full Text] [Related]
15. Synthetic biology in various cellular and molecular fields: applications, limitations, and perspective.
Safaei M; Mobini GR; Abiri A; Shojaeian A
Mol Biol Rep; 2020 Aug; 47(8):6207-6216. PubMed ID: 32507922
[TBL] [Abstract][Full Text] [Related]
16. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
17. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
18. T cell engineering as therapy for cancer and HIV: our synthetic future.
June CH; Levine BL
Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20140374. PubMed ID: 26416683
[TBL] [Abstract][Full Text] [Related]
19. Car T Cells in Solid Tumors: Overcoming Obstacles.
Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
